From Bench to Bedside: Translational Gene Therapy Breakthroughs for Inherited and Acquired Blindness

The 2025 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) highlighted a diverse range of gene therapy strategies for both inherited and acquired forms of blindness. Inherited blindness, resulting from genetic mutations passed from parents to offspring, often manifests at birth or early in life and typically worsens over time. Examples include Retinitis Pigmentosa (RP), Stargardt Disease, Usher Syndrome, and Leber Congenital Amaurosis (LCA). In contrast, acquired blindness develops later in life due to diseases such as glaucoma or Geographic Atrophy (GA), a late-stage manifestation of Age-Related Macular Degeneration (AMD).

A summary of key breakthroughs presented at the meeting is provided in Table 1, with detailed analysis discussed throughout this scientific review.

Table 1: Summary of Breakthroughs in Gene Therapy Breakthroughs for Inherited and Acquired Blindness

Gene Therapy for Retinitis Pigmentosa (RP)

Retinitis Pigmentosa (RP) is a genetically heterogeneous group of inherited retinal disorders characterized by progressive photoreceptor degeneration, leading to night blindness, peripheral vision loss, and eventually central vision impairment. With over 90 implicated genes and more than 3,000 known mutations, RP poses a significant therapeutic challenge. Currently, there is no cure. Symptom management and the FDA-approved gene therapy Luxturna, which targets RPE65 mutations, benefit only a small subset of patients. Nevertheless, advances in gene therapy, stem cell transplantation, optogenetics, and retinal implants are expanding the treatment landscape.

Despite the genetic complexity of RP, recent progress in gene therapy is encouraging. Mutation-specific and mutation-agnostic strategies, including CRISPR-based editing, AAV-mediated gene delivery, and light-sensitive opsins, are being actively pursued. Success in editing dominant mutations such as RHO and early clinical results with therapies like botaretigene sparoparvovec (RPGR gene) demonstrate promising functional improvements. Tools such as base editing, nanoparticle delivery, and optogenetic technologies continue to diversify the therapeutic arsenal. However, treatment efficacy remains dependent on the survival of residual photoreceptors, emphasizing the importance of early diagnosis and intervention.

New studies presented at the ASGCT 2025 meeting reflect a shift toward personalized and mutation-independent strategies for RP. Highlights include:

1. Mirtron-Based Gene Silencing for Dominant RP
   Researchers at the University of Oxford developed a triple-mirtron AAV therapy targeting the P23H mutation in the RHO gene. In a humanized mouse model of autosomal dominant RP, the treatment selectively silenced the mutant allele while preserving wild-type expression, leading to sustained photoreceptor function and structural integrity.
2. Subretinal AAV Therapy for X-Linked RP
   A Phase 1 trial of FT-002, an AAV5 vector encoding codon-optimized RPGR, demonstrated a favorable safety profile and measurable functional improvements in patients with X-linked RP. High-dose cohorts showed improvements in microperimetry and preservation of the ellipsoid zone, supporting further clinical development.
3. Gene Augmentation for MERTK-Related RP
   Opus Genetics’ OPGx-MERTK therapy preserved retinal structure and function in a dose-dependent manner in a rat model with MERTK mutations. The treatment significantly maintained the outer nuclear layer and improved scotopic ERG responses, highlighting its therapeutic potential for phagocytosis-related RP.
4. Mutation-Agnostic Gene Regulation
   Ocugen’s OCU400, an AAV5-NR2E3 gene therapy, demonstrated safe and durable expression in minipigs. By modulating a key transcription factor involved in retinal homeostasis, OCU400 offers a mutation-independent strategy applicable to RP and LCA.
5. BBS10 Gene Therapy for Syndromic RP
   An AAV8 vector targeting BBS10 achieved significant cone and rod function rescue in knockout mice. The RK promoter facilitated efficient and safe expression, suggesting its promise in treating Bardet-Biedl Syndrome-related RP.
6. Synthetic Opsins for Geographic Atrophy
   Nanoscope Therapeutics reported that AAV2-delivered multi-characteristic opsins (MCOs) slowed retinal degeneration and improved retinal function in non-human primates with induced GA, demonstrating cross-application potential beyond inherited retinal diseases.
7. Optogenetic Therapy for Advanced RP
   In a first-in-human trial, ZM-02, a PsCatCh2.0-based optogenetic AAV therapy, restored visual function in individuals with advanced RP. Participants experienced meaningful gains in visual acuity and color perception, offering hope for patients with extensive photoreceptor loss.
8. AAV-HITI for Mutation-Independent Editing
   A multidisciplinary team implemented homology-independent targeted integration (HITI) to deliver therapeutic DNA directly to the RHO locus in a P23H mouse model. The therapy restored retinal structure and function without the need for mutation-specific guides.
9. Next-Gen Optogenetics
   U-geneX introduced optimized light-sensitive ion channels for AAV delivery to retinal ganglion cells. These constructs restored vision in blind mice and demonstrated promising performance in non-human primates, underscoring their therapeutic promise in late-stage retinal degeneration.

Gene Therapy for Stargardt Disease / ABCA4-Related Retinopathies

Stargardt disease, the most common inherited macular dystrophy, is caused by mutations in the ABCA4 gene. These mutations lead to toxic accumulation of lipofuscin in the retina and progressive central vision loss, often beginning in adolescence. Current management is limited to UV protection and visual aids. Emerging therapies, such as SB-007 and VG-801, aim to restore ABCA4 function using novel splicing or gene replacement strategies. Other approaches—like the vitamin A analog ALK-001, CRISPR-Cas9 editing, and the RBP4 antagonist tinlarebant—show promise in slowing disease progression. The field is steadily advancing toward precision medicine, despite challenges related to the large size of the ABCA4 gene and the variability of disease progression.

Innovations such as dual AAV vectors and non-viral platforms (e.g., C3DNA/COMET) now enable delivery of full-length ABCA4, while exon editing and CRISPR-based therapies expand the scope of mutation coverage. Collectively, these approaches aim not just to manage symptoms but to alter disease trajectory.

Key highlights from ASGCT 2025 include:

1. Synthetic Opsin Therapy Enables Vision Restoration
   The Phase 2 STARLIGHT trial evaluated MCO-010, a synthetic opsin delivered via intravitreal AAV in Stargardt patients. The therapy was well-tolerated with only mild ocular adverse events. At 48 weeks, patients showed an average 5.5-letter improvement in best-corrected visual acuity (ETDRS), along with gains in mobility, magnifier use, and visual field performance—suggesting restored functional vision.
2. Intein-Based Dual AAV Gene Therapy Restores Full-Length ABCA4
   HuidaGene Therapeutics developed HG005, a dual AAV therapy using intein-mediated protein trans-splicing (PTS) to reconstitute full-length ABCA4. In Abca4-deficient mice, this strategy restored ABCA4 protein to beyond wild-type levels and reduced toxic A2E accumulation by 74.5%, highlighting its disease-modifying potential.
3. Splice Enhancer Boosts Dual AAV Expression
   The GROW Research Laboratory and collaborators introduced a 90 bp splice enhancer intron (SEI), which improved transgene activity up to 2.4-fold in vitro and enhanced expression in vivo. In Stargardt and DMD models, SEI-enabled vectors produced improved functional outcomes, supporting their utility across multiple genetic diseases.

Gene Therapy for Leber Congenital Amaurosis (LCA) / RPE65 Disorders

Leber Congenital Amaurosis (LCA) is a group of severe early-onset retinal dystrophies often caused by mutations in the RPE65 gene. Luxturna (voretigene neparvovec), the first FDA-approved gene therapy for a genetic disease, restores RPE65 function, improving vision and light sensitivity. Although transformative, its effects may wane over time, and it only addresses a fraction of LCA cases. Expanding the therapeutic toolbox to other genetic subtypes and improving long-term outcomes is an ongoing effort.

At ASGCT 2025, several developments underscored the growing sophistication and safety of next-generation gene therapies for LCA:

1. AIPL1-Associated LCA in Children
   MeiraGTx and University College London reported successful use of an AAV therapy targeting AIPL1. In a cohort of 11 children born blind, treatment restored visual acuity and retinal responses, demonstrating the value of early intervention in pediatric gene therapy.
2. Improved Safety with HG004 for RPE65-LCA2
   HuidaGene Therapeutics’ AAV9-based HG004, evaluated in the multinational LIGHT trial (NCT06088992), showed reduced chorioretinal atrophy compared to Luxturna. Only 33.3% of patients in low/mid-dose groups and none in the high-dose group developed this adverse effect, compared to up to 80% with Luxturna. HG004’s improved safety profile has earned Orphan Drug Designation in both the U.S. and EU.
3. Mutation-Agnostic Gene Therapy: OCU400
   Ocugen’s OCU400 (AAV5-hNR2E3) demonstrated sustained retinal expression in preclinical minipig models with no systemic toxicity. By modulating retinal transcriptional programs, this platform may benefit a broad range of RP and LCA subtypes, offering a mutation-independent therapeutic option.

Gene Therapy for Geographic Atrophy (GA) / Age-Related Macular Degeneration (AMD)

Geographic Atrophy (GA), a form of late-stage dry AMD, results from progressive retinal cell loss, often due to overactivation of the complement system. FDA-approved therapies like Syfovre and Izervay slow degeneration but do not restore vision. Gene therapy provides a more durable, mechanism-based approach that may reduce treatment burden and potentially halt or reverse disease progression.

Notable advances from ASGCT 2025 include:

1. AAV2 Gene Therapy Stability for Suprachoroidal Delivery
   Kriya Therapeutics and Everads Therapy conducted a rigorous stability study on an AAV2 vector for suprachoroidal injection. The vector maintained integrity and bioactivity across various dilutions and storage conditions, confirming its clinical readiness.
2. Dual-Action Gene Therapy (IKC159V)
   Ikarovec Limited’s bicistronic AAV therapy delivers PEDF and soluble CD46 to protect neurons and inhibit complement activity. In vitro and in vivo data showed improved survival of RPE cells and preserved visual function, supporting IKC159V’s candidacy for treating GA.
3. Complement Inhibition via CR2-CR1 Fusion (KRIYA-825)
   KRIYA-825 potently inhibited both classical and alternative complement pathways (IC₅₀ < 1 nM). In animal models, it preserved retinal structure and achieved targeted expression with minimal systemic exposure.
4. Optogenetic Therapy for GA Using MCOs
   Nanoscope Therapeutics reported that a single AAV2-MCO injection slowed degeneration and improved retinal function in non-human primates with GA, offering a non-invasive optogenetic solution for vision restoration.
5. CRISPR-Cas13 for nAMD (HG202)
   HG202 reduced VEGFA expression and retinal thickness in early Phase 1 data, with no serious adverse events. The therapy significantly reduced injection frequency, hinting at durable disease control.
6. Dual-Acting AAV2.NG Vector for nAMD
   A team of researchers from Akron Children’s Hospital has developed an engineered AAV2 capable of delivering both anti-VEGF and anti-inflammatory genes via intravitreal injection. Preclinical data support its efficacy and potential as a minimally invasive nAMD therapy.
7. RM-102: Long-Term CRISPR Therapy for nAMD
   Reforgene Medicine’s RM-102, a CRISPR/Cas13 system targeting VEGFA mRNA, showed long-term efficacy in reducing CNV in mice and primates without toxicity for 275 days, matching the performance of Eylea.

Gene Therapy for Usher Syndrome

Usher syndrome is a rare inherited disorder characterized by combined hearing loss, progressive vision impairment from retinitis pigmentosa (RP), and in some cases, vestibular dysfunction. It is the most common cause of combined deafness and blindness, classified into three types based on severity and age of onset. While supportive care such as cochlear implants, mobility training, and low-vision aids are standard, there is currently no approved therapy that targets the underlying genetic causes.

Gene therapy offers transformative potential by addressing the root mutations responsible for Usher syndrome. However, the large size of genes such as USH2A and PCDH15 has posed a significant barrier to traditional AAV-based delivery. Innovations like protein minimization, dual-vector systems, RNA-based drugs, and gene editing with CRISPR are now beginning to overcome these limitations.

Key studies presented at ASGCT 2025 include:

1. Mini-PCDH15 Gene Therapy for USH1F
   A collaboration between Harvard Medical School, the University of Oregon, and Mass Eye and Ear developed a compact version of the PCDH15 gene for AAV delivery. This “mini-PCDH15” construct excluded 5 of 11 extracellular cadherin domains while preserving therapeutic functionality. Subretinal delivery in zebrafish and mice restored photoreceptor structure and visual responses, supporting its viability as a gene therapy candidate for Usher Syndrome Type 1F (USH1F).
2. Full-Length PCDH15 via RNA End Joining (REJ)
   The Salk Institute and Insmed Gene Therapy introduced an innovative REJ strategy to reconstitute full-length PCDH15 using AAV-delivered gene fragments. In HEK293T cells, REJ constructs achieved seamless splicing and robust expression of full-length protein. In mice, subretinal injection resulted in functional rescue and appropriate photoreceptor localization, demonstrating a scalable approach to deliver large genes.
3. Gene Replacement Therapy for USH1C
   Louisiana State University and the University of Florida developed a gene replacement strategy for Usher Syndrome Type 1C using an AAV44.9(E531D) vector carrying human USH1C. In a mouse model harboring the pathogenic c.216G>A mutation, subretinal injection at postnatal day 21 led to widespread photoreceptor transduction, strong gene expression, and significant improvement in visual function. This study validates long-term gene replacement for treating USH1C-associated RP.

Gene Therapy for Friedreich’s Ataxia (FA)

Friedreich’s Ataxia (FA) is a progressive neurodegenerative disorder caused by GAA repeat expansions in the FXN gene, leading to frataxin deficiency. The disease results in mitochondrial dysfunction, spinal cord and nerve degeneration, and often cardiomyopathy. While omaveloxolone (Skyclarys™), approved in 2023, provides the first disease-modifying treatment, it does not address the root genetic defect. Gene therapy strategies aim to restore frataxin expression systemically to prevent or reverse neurological and cardiac damage.

At ASGCT 2025, two landmark studies expanded the scope of gene therapy in FA:

1. Ocular Gene Therapy Preserves Vision in FA Models
   Researchers at the University of Florida developed an ocular FA model with RGC-specific frataxin knockout (Pou4f2-FXN KO), which recapitulated progressive visual decline. Intravitreal delivery of AAV.P2-V1 encoding human FXN preserved retinal layers and improved visual function, as measured by pattern electroretinography (pERG). These findings highlight the feasibility of localized gene therapy to prevent vision loss in FA patients.
2. CAP-004: Systemic AAV Gene Therapy for Multisystem FA
   Capsida Biotherapeutics introduced CAP-004, an engineered AAV vector optimized for CNS and cardiac transduction. Compared to AAV9, CAP-004 achieved a 100-fold increase in CNS expression and reduced liver tropism in non-human primates. A single IV dose resulted in widespread FXN expression in Purkinje neurons, spinal motor neurons, heart tissue, and even retina. CAP-004 was well-tolerated, with no toxicity or immunogenicity observed, positioning it as a strong candidate for clinical translation in multisystem FA therapy.

RNA-Based Gene Therapy for CLN3 Batten Disease

CLN3 Batten disease is the most common form of neuronal ceroid lipofuscinosis (NCL), a fatal pediatric neurodegenerative disorder. Caused by mutations in the CLN3 gene, it leads to early-onset vision loss, behavioral changes, seizures, cognitive decline, and eventually death in early adulthood. Current treatment is limited to supportive care.

A major breakthrough presented at ASGCT 2025 came from a multi-institutional team led by the University of Michigan, Rosalind Franklin University, and Sanford Research. They developed an antisense oligonucleotide (ASO) therapy, Zebronkysen, targeting the c.569dupG mutation in exon 8 of the CLN3 gene. The ASO promotes exon skipping to restore the reading frame and produce functional protein.

In a pig model of CLN3 disease, a single intravitreal injection of Zebronkysen achieved sustained exon 8 skipping and functional rescue of the retina for up to 12 months. The therapy also demonstrated effective frame correction in patient-derived cells. Remarkably, Zebronkysen was approved by the FDA under an “n-of-1” compassionate use framework and is currently being used to treat twin patients with the rare mutation. This case exemplifies the growing potential of RNA-based precision medicine for ultra-rare genetic diseases.

Conclusion

The 2025 ASGCT meeting marked a turning point in the field of ocular gene therapy, highlighting rapid advancements in both inherited and acquired forms of blindness. From mutation-specific therapies for RP, LCA, and Stargardt disease to mutation-agnostic approaches for AMD and Batten disease, the landscape is increasingly defined by personalization, safety, and durability. Novel delivery systems, RNA-based strategies, and optogenetic tools are expanding the reach of gene therapy to previously untreatable conditions. As preclinical successes translate into clinical milestones, these breakthroughs bring us closer to a future where blindness from genetic and degenerative diseases is not only treatable, but potentially reversible.

Reference

ASGCT 2025 Meeting Abstracts 

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1.  Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217
2. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. bioRxiv 2025.04.15.648836v1 https://www.biorxiv.org/content/10.1101/2025.04.15.648836v1
3.  American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity  Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)

• ADME/Tox
• Molecular Biology
• The Art of Cell Culture
• Exosomes
• Stability Services
• Potency Assay
• Gene Therapy Assays
• Immunotherapy Assays
• Antiviral Therapy Assays
• cGMP
• MLR
• Cell Based Assays
• ELISA
• Flow Cytometry
• Protein
• PCR-qPCR
• Immunoassay
• Radioimmunoassay
• GLP
• Transfection
• Cell Therapy Assays
• Targeted Protein Degradation
• Research to Commercialization